Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Nicht-invasive Neurostimulation als Werkzeug für Diagnostik und Management von neurodegenerativen Erkrankungen

29. September 2026 aktualisiert von: Eino Solje, Kuopio University Hospital

Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.

Studienübersicht

Detaillierte Beschreibung

Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.

Studientyp

Interventionell

Einschreibung (Geschätzt)

200

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Kuopio, Finnland
        • Rekrutierung
        • Kuopio University Hospital
        • Kontakt:
          • Eino Solje

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Mild Cognitive Impairment due to Alzheimer's disease
  • Dementia with Lewy Bodies
  • Frontotemporal dementia
  • Idiopathic normal pressure hydrocephalus (iNPH)

Exclusion Criteria:

  • History of seizures
  • Pregnancy
  • Metal implants in the head (except dental fillings)
  • Electronic implants (i.e. pace-maker, implanted medical pump)
  • Age <18 years

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Real tACS

Four sessions (once a day, during four consecutive days) of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)

Single session of gamma tACS (40 Hz) over the superior parietal cortex

Placebo-Komparator: Sham tACS

Four sessions of sham tACS (once a day, during four consecutive days) over the superior parietal cortex (Precuneus)

Single session of gamma tACS (40 Hz) over the superior parietal cortex

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Changes in Rey Auditory Verbal Learning Test score
Zeitfenster: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention

Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. Another list of 15 unrelated words are given and the patient must again repeat the original list of 15 words and then again after 30 minutes.

The examiner reads aloud 15 unrelated words and the participant is asked to recall the words after each of the five trials. After a 15 minute delay, the participant is asked again to recall the words. The score ranges from 0 (worst performance) to 75 (best performance).

Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
Changes in Rey Auditory Verbal Learning Test, recognition
Zeitfenster: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention

Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat.

After a 15 minute delay, the participant is asked to recognise the original 15 words intermixed with 31 distractor words. The score of the recognition part ranges from 0 (worst performance) to 46 (best performance).

Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
Changes in orientation to time and place (MMSE questions 1-10)
Zeitfenster: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention

10 questions about the orientation. The score ranges from 0 (worse performance) to 10 (best performance).

Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
Changes in Trail Making A & B tests
Zeitfenster: Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention

TMT A & B tests. Time to perform set is recorded.

Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
Changes in INECO Frontal Screening test
Zeitfenster: Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention

Test battery assessing frontal lobe functions. The score ranges from 0 (worse performance) to 30 (best performance)

Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
Changes in phonemic fluency
Zeitfenster: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention

Person is requested to provide as many words as possible starting with certain letter. The score is the sum of all acceptable words produced in one minute.

Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in SAI measurements
Zeitfenster: Baseline (immediately before the intervention), immediately after the last intervention

By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short latency afferent inhibition (SAI), which is a marker of cholinergic neurotransmission.

Baseline (immediately before the intervention), immediately after the last intervention
Change in SICI measurements
Zeitfenster: Baseline (immediately before the intervention), immediately after the last intervention

By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short interval intracortical inhibition (SICI), which is a marker of gabaergic neurotransmission.

Baseline (immediately before the intervention), immediately after the last intervention
Change in ICF measurements
Zeitfenster: Baseline (immediately before the intervention), immediately after the last intervention

By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on intracortical facilitation (ICF), which is a marker of glutamatergic neurotransmission.

Baseline (immediately before the intervention), immediately after the last intervention
Change in modified Frontal Behavioral Inventory (FBI-mod) score
Zeitfenster: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention

The modified Frontal Behavioral Inventory (FBI-mod) is used to assess behavioral symptoms associated with frontotemporal dysfunction. The questionnaire evaluates changes in behavioral and personality features. Higher scores indicate a greater severity of behavioral symptoms.

Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
Change in Neuropsychiatric Inventory (NPI) score
Zeitfenster: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention

The Neuropsychiatric Inventory (NPI) is used to assess neuropsychiatric symptoms, including their frequency and severity. Higher total scores indicate a greater burden of neuropsychiatric symptoms.

Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Eino Solje, MD, PhD, Kuopio University Hospital

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

21. November 2022

Primärer Abschluss (Geschätzt)

1. Juli 2032

Studienabschluss (Geschätzt)

1. Juli 2032

Studienanmeldedaten

Zuerst eingereicht

23. März 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. April 2022

Zuerst gepostet (Tatsächlich)

14. April 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

2. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

29. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Pseudonymized data upon request, according to Finnish national and EU GDPR regulations

IPD-Sharing-Zeitrahmen

Data will be shared after the study completion indefinitely.

IPD-Sharing-Zugriffskriterien

Reasonable request

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren